Brian Brille Net Worth 2026: Caris Life Sciences Vice Chairman

No reputable outlet has published an estimate of Brian Brille's net worth. The $11.3 million figure and the "$41 million a year" income that appeared on this page before had no source, and the page also described him wrongly as the CEO of Caris Life Sciences. What public filings do show is a large, measurable stake: Brille is vice chairman and executive vice president of Caris Life Sciences, the Nasdaq-listed cancer testing company, and its 2026 proxy statement lists him as the beneficial owner of about 3.9 million shares. In September 2026 he sold 400,000 of them for $12.1 million.

What is Brian Brille's net worth?

No Forbes list, Bloomberg index or business publication puts a figure on his wealth. The best public evidence is his Caris holding. According to the proxy statement filed in April 2026, he beneficially owned 3,911,807 Caris shares, or 1.4% of the company, a total that includes stock options and shares held by family trusts. Share prices move daily, options carry an exercise cost and trust shares are only partly his, so that number cannot be turned into a clean net worth.

He also spent about 14 years as a senior executive at Bank of America Merrill Lynch and over a decade before that at Morgan Stanley, and property records reported in the press show multimillion-dollar homes. Because no outlet has combined these into a published estimate, we do not show a figure. The $11.3 million once shown here had no source.

Where his money comes from

Caris Life Sciences stock

Caris, based in Irving, Texas, sells molecular profiling tests that help doctors choose cancer treatments. Brille joined as vice chairman, executive vice president and board member in January 2018. The company went public on Nasdaq in June 2025 at $21 a share, raising more than $494 million, and closed its first day at $28, MD+DI reported.

On September 17, 2026, Brille exercised 400,000 fully vested options at $2.44 a share (a cost of $976,000) and sold the same number of shares at an average of $30.33, for $12.13 million, according to Investing.com. After the sale he held 230,303 shares directly and 500,000 more through a family trust.

Wall Street career

Before Caris, Brille was an investment banker. His salary and bonuses from those years were not disclosed individually, but he held some of the most senior banking roles at Bank of America.

Career timeline

FinanceAsia reported his Asia Pacific appointment in September 2009, saying he was chosen to lead the integration of Bank of America's and Merrill Lynch's corporate and investment banking teams in the region after the 2009 takeover. At Caris he was the company's voice on its 2021 $830 million growth equity round, and he has spoken on earnings calls about the company's finances, including the second-quarter 2026 call.

Education

The Caris proxy statement says he holds a bachelor's degree in accounting from the University of Illinois, a Master in Public Policy from the Harvard Kennedy School and a law degree (JD) from Stanford Law School. The earlier version of this page had the order wrong.

Age

The 2026 proxy statement gives his age as 65 as of April 23, 2026. The New York Times reported on his 50th birthday party in Hong Kong in September 2010, which fits. The height and weight on this page earlier had no source and have been removed.

Related: Brian Haney Net Worth

Wife, family and homes

The New York Observer reported in 2008 that Brille and his wife, Leslie Simmons Brille, had two young children. The earlier version of this page named a different woman as his wife; we found no source for that and have removed it.

The couple bought the former Jim Henson townhouse at 117-119 East 69th Street in Manhattan for $12.4 million in May 2005 and listed it for $32 million in April 2008, the Observer reported. It sold later that year for $28.5 million to Edgar Bronfman Jr. and his wife, according to the paper.

Board and charity roles

• Trustee, Cancer Research Institute, a non-profit that funds cancer research.
• Director since 2022, International Biomedical Research Alliance, which supports the NIH Oxford-Cambridge Scholars Program.

Recent changes (2025 to 2026)

The June 2025 IPO turned his private Caris stake into publicly traded shares. By September 2026 the stock traded near a 52-week high of $34.54 after Caris reported second-quarter revenue of $263.7 million, up 45% from a year earlier, according to Investing.com. That rally is the backdrop for his $12.1 million sale.

Read also: Brian J Esposito Net Worth

How this page was checked

We used the Caris 2026 proxy statement, Investing.com's report of his Form 4 filing, MD+DI, FinanceAsia, BioSpace, the New York Observer and the New York Times. We removed the unsourced net worth, the income table, the wrong CEO title, the wrong spouse, and the height and weight.